Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NVLyOFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LFWGlEPTB;NT64OlY3KM7:TR?= MWrTRW5ITVJ?
DOHH-2 M2nCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDlSo5KSzVyPUmuN|U3QDlizszN NHfncWVUSU6JRWK=
no-10 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSxU5dnUUN3ME25MlkxOzlizszN MkTpV2FPT0WU
LS-513 NW[2U3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqwO5RKSzVyPUGxMlM2PDdizszN MXrTRW5ITVJ?
ALL-PO NXvlNFBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH1TWM2OD1zMT63O|M1KM7:TR?= Mkj5V2FPT0WU
8-MG-BA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\tTWM2OD1zMz6xNVI{KM7:TR?= NHO2XHFUSU6JRWK=
RPMI-8402 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i1WWlEPTB;MUWuPFU{PyEQvF2= M{DyRnNCVkeHUh?=
EoL-1-cell M1\ZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDIZ5JKSzVyPUG4MlU6PDhizszN NEj1OHdUSU6JRWK=
NALM-6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjG[o5KSzVyPUG5MlAyPjdizszN M1Ow[XNCVkeHUh?=
DEL MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHqTWM2OD1{MD6xOFcyKM7:TR?= NG\SZlZUSU6JRWK=
SR M4PMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJ|Lk[3NVUh|ryP NUnWd5N[W0GQR1XS
697 NVTYems1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu2XHlKSzVyPUK2MlYyPTVizszN MWDTRW5ITVJ?
COLO-829 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXINVlKSzVyPUK2Mlg1QDNizszN Mkj6V2FPT0WU
EVSA-T NVHZc5BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHwTWM2OD1{Nz61OVYyKM7:TR?= NIXTTZFUSU6JRWK=
ATN-1 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLuTWM2OD1|MT6yN|I6KM7:TR?= MmfkV2FPT0WU
L-363 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LwTmlEPTB;M{GuO|Q3OSEQvF2= MnL6V2FPT0WU
LAMA-84 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1foNWlEPTB;M{KuOVIyOSEQvF2= NX\2[YpyW0GQR1XS
NOS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICzb2tKSzVyPUO0MlI6PTZizszN MkLkV2FPT0WU
BB30-HNC NUn1Rm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jSc2lEPTB;M{SuN|MxPiEQvF2= MmjCV2FPT0WU
BC-1 NHXsVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T1SmlEPTB;M{euPVc1PiEQvF2= NXHwcG1tW0GQR1XS
IST-SL2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfyTWM2OD1|OD6yNlQh|ryP MU\TRW5ITVJ?
D-392MG NE\Ie4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3SmxKSzVyPUSwMlIzOTVizszN MYjTRW5ITVJ?
no-11 M1THOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXTWM2OD12MD61OVIyKM7:TR?= MVjTRW5ITVJ?
LC4-1 NYm1c5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD5co5GUUN3ME20NE45PzF4IN88US=> NGD3eFRUSU6JRWK=
A388 NHfmO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUeyNW1OUUN3ME20Nk42QDR6IN88US=> NVXFeXduW0GQR1XS
NTERA-S-cl-D1 NITZU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTR{LkewO|Qh|ryP M3jHRnNCVkeHUh?=
CESS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTYV3VuUUN3ME20OE4zOjN{IN88US=> MUnTRW5ITVJ?
RS4-11 NInEVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzDcWZsUUN3ME20PU4xQTN6IN88US=> Mm[0V2FPT0WU
MS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPaTWM2OD13MD65N|UyKM7:TR?= M2Tqe3NCVkeHUh?=
CTV-1 M2S1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorOTWM2OD13MT6wO|Qh|ryP MnLrV2FPT0WU
D-502MG NXHWTYI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILIOWdKSzVyPUWxMlYzPzFizszN NYHGXYNsW0GQR1XS
ML-2 NYfIVGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTV{LkmxPVUh|ryP M13GcXNCVkeHUh?=
SK-NEP-1 M3vsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTV|LkO5NlMh|ryP NH\zbJJUSU6JRWK=
LOXIMVI M3rXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfxNXU4UUN3ME21N{42QDh2IN88US=> NVqwdmlXW0GQR1XS
DJM-1 NH7teJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzxfXlKSzVyPUW2MlM{QTFizszN NXLofmE2W0GQR1XS
GI-1 M1:zRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT4fpVKSzVyPUW2MlYyPDlizszN NGjMV2tUSU6JRWK=
IST-MES1 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjXOo9FUUN3ME22NE42PDl|IN88US=> NIrRSlVUSU6JRWK=
MV-4-11 M3XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH6TYtKSzVyPU[wMlY2OzhizszN NFfxdJRUSU6JRWK=
OVCAR-4 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn76TWM2OD14Mz61OlU4KM7:TR?= M2WyUHNCVkeHUh?=
KE-37 NF7nfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTZ4LkK2Olgh|ryP M3TN[nNCVkeHUh?=
D-542MG M4jlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLTWM2OD14OD60NVM2KM7:TR?= MUTTRW5ITVJ?
MHH-PREB-1 NULyWYl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDPWHI2UUN3ME23Nk45PDRzIN88US=> NVzWPFZlW0GQR1XS
MRK-nu-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLtV5dKSzVyPUezMlQ4ODVizszN MWLTRW5ITVJ?
D-247MG MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\1XoxKSzVyPUezMlU1PDJizszN NUDBW|BOW0GQR1XS
OCI-AML2 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfLcXVKSzVyPUe2Mlk{PjlizszN MVrTRW5ITVJ?
LP-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorFTWM2OD16Mj64O|MyKM7:TR?= MXHTRW5ITVJ?
HCC1599 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnHcGRbUUN3ME24OE4zQDN5IN88US=> NGXscVFUSU6JRWK=
KARPAS-45 NFy4dpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTh2Lk[5PVIh|ryP M3fXNnNCVkeHUh?=
BE-13 NYfSNpNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm3RWtKSzVyPUm5MlA1PzdizszN NX3O[mhZW0GQR1XS
GCIY MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTl7LkC5OVQh|ryP NWjGc4NJW0GQR1XS
BV-173 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi3eYEzUUN3ME2xNFAvOzJ3IN88US=> NVv5OW54W0GQR1XS
LB2518-MEL MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TEeWlEPTB;MUCwMlc5QSEQvF2= MVTTRW5ITVJ?
KS-1 NX3keG1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFyMT62N|kh|ryP NYDTcI5XW0GQR1XS
MOLT-16 NF\5[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFyND65PFYh|ryP NUHBTVljW0GQR1XS
NCI-H1770 NWjKOmNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXjfIxKSzVyPUGwPE44QDRizszN NEO1cmZUSU6JRWK=
NCI-H82 NHXQVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSwTWM2OD1zMUCuPVc3KM7:TR?= MmHDV2FPT0WU
NCCIT MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf6NJpKSzVyPUGxNk42OjlizszN M3jqNnNCVkeHUh?=
KALS-1 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjiZYs1UUN3ME2xNVUvQTRzIN88US=> M2n1WnNCVkeHUh?=
LB2241-RCC M3:1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;iPHRKSzVyPUGxOk43PzlizszN M{nQdHNCVkeHUh?=
HH M4G4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37SdWlEPTB;MUG3MlM6PSEQvF2= NIe4dIlUSU6JRWK=
HD-MY-Z MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\mTWM2OD1zMUiuOFg5KM7:TR?= MULTRW5ITVJ?
EB-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXqTWM2OD1zMkOuNFk1KM7:TR?= NEO5XHVUSU6JRWK=
BL-70 NV3mfo5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rSWmlEPTB;MUKzMlEzPyEQvF2= NIHPVYtUSU6JRWK=
K-562 M2rjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqyTWM2OD1zMk[uNlQ2KM7:TR?= M{f3fXNCVkeHUh?=
HT-144 NWLWS|ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGyPXVKSzVyPUGzN{4yPjRizszN NFfUVGpUSU6JRWK=
PF-382 NYTWNG5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HmVWlEPTB;MUO0MlM3OSEQvF2= MVrTRW5ITVJ?
RPMI-8226 NF:wfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLGbI5KSzVyPUGzOU4xPDVizszN M3LHTnNCVkeHUh?=
NCI-H1355 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXVVXhKSzVyPUGzOU42QDdizszN MmPxV2FPT0WU
LXF-289 M2HvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF|OT63PFEh|ryP MYjTRW5ITVJ?
NCI-H69 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvjTWM2OD1zNEKuPVMzKM7:TR?= MYPTRW5ITVJ?
SK-MEL-1 NYCwcZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF2Nz6xN{DPxE1? NV:0U4dIW0GQR1XS
KARPAS-299 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vwZWlEPTB;MUS5MlEzKM7:TR?= M{SyeHNCVkeHUh?=
GB-1 NEfqR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF2OT6zNlIh|ryP M2G5eHNCVkeHUh?=
CMK MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTWVJdKSzVyPUG0PU42OTVizszN MkLwV2FPT0WU
MPP-89 NFHDWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv5OIZKSzVyPUG1Ok4xOzVizszN M4jvdHNCVkeHUh?=
KU812 NEPLdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT3TGg{UUN3ME2xOlEvQTB{IN88US=> MV7TRW5ITVJ?
REH MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LLUWlEPTB;MU[yMlEzPSEQvF2= NXG4[XV6W0GQR1XS
NEC8 NVTtPYd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HJVGlEPTB;MU[1MlAzPiEQvF2= MVTTRW5ITVJ?
KP-N-YS NHHOV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF4OD6zPVUh|ryP MnXIV2FPT0WU
Ramos-2G6-4C10 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDCTWM2OD1zNkmuPVE2KM7:TR?= NEe0cpNUSU6JRWK=
Becker NV71b|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrve|MzUUN3ME2xO|QvOThizszN NYrxV3B2W0GQR1XS
LB647-SCLC NFTCSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[wVGROUUN3ME2xO|UvQDR3IN88US=> M3PLPXNCVkeHUh?=
LU-139 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzCTWM2OD1zN{iuNFE6KM7:TR?= M3rC[nNCVkeHUh?=
QIMR-WIL M2\MVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nZVmlEPTB;MUe5MlY1PiEQvF2= NEnXSGZUSU6JRWK=
NCI-H1395 NVHhSnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULGS|ZrUUN3ME2xO|kvQTl4IN88US=> NELROmdUSU6JRWK=
NOMO-1 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlKyTWM2OD1zOEKuPFUh|ryP NXPDboxzW0GQR1XS
GI-ME-N MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPOTWM2OD1zOEeuPVY6KM7:TR?= NH\WWJNUSU6JRWK=
KMS-12-PE MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzDemd{UUN3ME2xPFkvOjd|IN88US=> NGjYN4tUSU6JRWK=
Daudi M4LG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXYTWM2OD1zOUGuNVI5KM7:TR?= MWTTRW5ITVJ?
LB996-RCC NH;VbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF7MT62PVkh|ryP MnzCV2FPT0WU
NCI-H2107 Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m1T2lEPTB;MUmzMlc{QSEQvF2= NEDYZmlUSU6JRWK=
SK-PN-DW NULRcJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjwR4c3UUN3ME2xPVQvPzF7IN88US=> M1rENXNCVkeHUh?=
MC-CAR M1LiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfXTWM2OD1{MEKuNlU{KM7:TR?= M3nycnNCVkeHUh?=
SNB75 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsTWM2OD1{MkGuPVQh|ryP MXTTRW5ITVJ?
ES4 M4q5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnKW|JKSzVyPUKyN{44QDNizszN MUHTRW5ITVJ?
KARPAS-422 NFTHfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UXWdKSzVyPUKyPE4{PTJizszN MXLTRW5ITVJ?
NCI-H1648 MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq1TWM2OD1{MkmuOFg6KM7:TR?= NY\4TVVtW0GQR1XS
ES6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfJSWtOUUN3ME2yN|kvPDNizszN MmLLV2FPT0WU
KNS-81-FD NXnUOm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjkXpR7UUN3ME2yOFEvOTl5IN88US=> MUnTRW5ITVJ?
JAR MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrOe3ZCUUN3ME2yOVYvOjJ3IN88US=> MXjTRW5ITVJ?
NB1 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljGTWM2OD1{NkCuOVE3KM7:TR?= NUTqeplrW0GQR1XS
D-336MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnqbGs3UUN3ME2yOlAvPjl6IN88US=> M1TCZ3NCVkeHUh?=
BC-3 M17lUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJ4NT6xO|gh|ryP MofoV2FPT0WU
HCC2218 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7VTWM2OD1{Nk[uOFE2KM7:TR?= M2n3[nNCVkeHUh?=
TE-9 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjLTWM2OD1{Nk[uOlI4KM7:TR?= NWHSSGFqW0GQR1XS
LB1047-RCC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ4Nj63OVMh|ryP M2L4NXNCVkeHUh?=
CTB-1 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnpeZJKSzVyPUK2PU46PzNizszN MVTTRW5ITVJ?
NB7 NX;NPHBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLuTWM2OD1{N{Gg{txO NYD5RVBrW0GQR1XS
ST486 NFzYVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO4RWw6UUN3ME2yO|cvPDF{IN88US=> MnnuV2FPT0WU
HCC1187 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ6Mj64NVEh|ryP MUDTRW5ITVJ?
NCI-SNU-16 M4CxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnqTWM2OD1{OESuNlQ5KM7:TR?= NXHGZYNJW0GQR1XS
COR-L279 NGjMVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjCcWJbUUN3ME2yPVEvPTh2IN88US=> MmWxV2FPT0WU
ES8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvqPVNxUUN3ME2yPVQvOTh{IN88US=> MofIV2FPT0WU
U-698-M NX7i[5ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe2XmhKSzVyPUK5PE4zPDNizszN NVv6dIdlW0GQR1XS
HEL M4HMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLDTWM2OD1|MEmuNVQ6KM7:TR?= NIDQNXpUSU6JRWK=
KINGS-1 NWPDNldYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNzMD62O|Qh|ryP NFvIWFZUSU6JRWK=
KY821 M3Llbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTN|Nj61PVUh|ryP NUTafmVCW0GQR1XS
MZ1-PC NInGW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\jOoZRUUN3ME2zOFUvPjF6IN88US=> MWDTRW5ITVJ?
LS-411N NYfI[nFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfwTWM2OD1|NUSuOlYh|ryP NVHHO|NmW0GQR1XS
SIG-M5 NHvsTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7QTWM2OD1|NUmuO|gzKM7:TR?= MYHTRW5ITVJ?
HT NVTaNmp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnkTWM2OD1|NkeuO|EyKM7:TR?= Ml\sV2FPT0WU
HC-1 NUXIcnJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjqOodrUUN3ME2zOlcvPzh5IN88US=> MnPGV2FPT0WU
NCI-H1694 M4L2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LEPWlEPTB;M{eyMlk{PCEQvF2= MnP6V2FPT0WU
BB65-RCC M3PXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;3TWM2OD1|N{[uNlQ2KM7:TR?= MXvTRW5ITVJ?
HAL-01 M4HGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHrWnJXUUN3ME2zO|kvQDN6IN88US=> MYDTRW5ITVJ?
ARH-77 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOyTWM2OD1|OUSuNFA5KM7:TR?= MYnTRW5ITVJ?
MZ7-mel MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\lTWM2OD1|OUeuNlM{KM7:TR?= M2PXXXNCVkeHUh?=
SIMA NYDyOHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ycGlKSzVyPUSwN{46OzNizszN NID6[4RUSU6JRWK=
DG-75 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fKPWlEPTB;NEG1MlY6QCEQvF2= NYiyfpRvW0GQR1XS
HUTU-80 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXmdXp5UUN3ME20NVkvOTh3IN88US=> NWHpWWpVW0GQR1XS
KNS-42 M373SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj3[|hKSzVyPUSyOU45OTVizszN NYGyeXU4W0GQR1XS
SH-4 NEWzVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCwTWM2OD12MkeuOVY2KM7:TR?= NGTvXZFUSU6JRWK=
L-540 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnsc3AyUUN3ME20N|EvODNzIN88US=> MlfiV2FPT0WU
NB10 M1K2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTR2MT6yN|Qh|ryP NFz6bnBUSU6JRWK=
ES1 NGj1e3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLtTWM2OD12NUKuO|U{KM7:TR?= MnHWV2FPT0WU
KMOE-2 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTR3Nj63NVEh|ryP Ml\zV2FPT0WU
MC116 M4Hpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LG[2lEPTB;NEW4MlEyPiEQvF2= MojTV2FPT0WU
RCC10RGB M{DQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR4MD6wNFUh|ryP Ml\mV2FPT0WU
RL95-2 NXnLcpYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTR4MD6yN|ch|ryP M4LDb3NCVkeHUh?=
Raji M2HZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXLO4NzUUN3ME20OlgvOTR|IN88US=> NHWwRpRUSU6JRWK=
CAS-1 NUS0U2ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT6Nm5sUUN3ME20O|IvODd|IN88US=> NX\SV2d5W0GQR1XS
Calu-6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnaUpdxUUN3ME20O|UvOjZ3IN88US=> NHHpZ29USU6JRWK=
KG-1 NUWzWVFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR5OD60OEDPxE1? NFq5cXNUSU6JRWK=
LB771-HNC Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDodYo{UUN3ME20PFIvOjN{IN88US=> MW\TRW5ITVJ?
ACN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTR7Mz61PVkh|ryP MYjTRW5ITVJ?
KM12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn21TWM2OD12OU[uOVg6KM7:TR?= NVS2coRTW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL (24.29 mM) warming
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO <1 mg/mL
In vivo 10% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID